IMMUNOTHERAPY BRIDGE
November 30th - December 1th 2022
SCIENTIFIC PROGRAM
Wednesday, Dec 1st, 2021
10:30 am
Introduction and objectives
Paolo A. Ascierto
SITC SESSION
LESSONS LEARNED FROM CELL THERAPIES
Chairpersons: Patrick Hwu, Bernard A. Fox
10:40 am
CAR-T
Chrystal Paulos
10:55 am
Targeting solid malignancies with ‘public’ neoantigen-specific T cell receptors
Christopher Klebanoff
11:10 am
Harnessing the power of a natural killer: bringing NK cells to immuno-oncology
Tamara Laskowski
11:25 am
Understanding resistance to develop better CAR T immunotherapies
Marco Ruella
11:40 am
Best of SITC 2021 for clinical development and trials
Paolo A. Ascierto
11:55 am
Discussion
12:25 pm
LECTURE – Immunotherapy in Renal Cell Carcinoma: update and new perspectives
Chairperson: Paolo A. Ascierto
Speaker: Giuseppe Procopio
12:55 pm
Lunch**
01:45 pm
SYMPOSIUM – Combinations therapy across cancers
Chairperson: Paolo A. Ascierto
NSCLC, Cesare Gridelli – RCC, Camillo Porta – Melanoma, Paolo A. Ascierto
SESSION 2
TRENDS IN IMMUNOTHERAPY
Chairpersons: John B. Haanen, Sandro Pignata
02:35 pm
Integrating Head and Neck Cancer Immunotherapy into Locally Advanced Treatment
Robert Ferris
02:50 pm
Pancreatic Cancer
Elizabeth Jaffee
03:05 pm
Kidney Cancer
Sergio Bracarda
03:20 pm
GI cancer
Antonio Avallone
03:35 pm
Implications of the Tumor Microenvironment for Breast Cancer Immunotherapy
Leisha A. Emens
03:50 pm
Ovarian Cancer
Sandro Pignata
04:05 pm
Coffee Break**
04:20 pm
PDI-blockade for Hodgkin Lymphoma: results, challenges and opportunities
Antonio Pinto
04:35 pm
Lecture: Merkel Cell Carcinoma
Paolo A. Ascierto
04:50 pm
Discussion
GREAT DEBATE SESSION
Chairpersons: Paolo A. Ascierto, Bernard A. Fox, Patrick Hwu, Igor Puzanov
05:20 pm
Have B-cells a therapeutic role in the response to cancer immunotherapy? Yes or No
Wolf Fridman, Tullia Bruno
05:50 pm
Discussion
06:00 pm
Intralesional therapy: oncolytic virus VS other specific immune modulators
Igor Puzanov, Omid Hamid
06:30 pm
Discussion
06:40 pm
Do early surrogates correlate with long-term overall survival? Yes or No
Michael A. Postow, Jeffrey Sosman
07:10 pm
Discussion
IMMUNOTHERAPY BRIDGE
December 1st-2nd, 2021
SCIENTIFIC PROGRAM
Thursday, Dec 2nd, 2021
SESSION 3
DRIVERS OF IMMUNE RESPONSES
Chairpersons: Alfredo Budillon, Bernard A. Fox
09:00 am
Biotechnology tricks to harness CD137 (4-1BB) costimulation for cancer
immunotherapy
Ignacio Melero Bermejo
09:15 am
Super CD8-T cells, a new tool in immunotherapy; T cell reprograming
Samir Khleif
09:30 am
Immunotherapy for non-immunogenic tumors
Nina Bhardvaj
09:45 am
Role of dendritic cells in immune response
Joshua Brody
10:00 am
Pre-existing immune contexture for immunotherapy response
Jerome Galon
10:30 am
Discussion
10:45 am
Coffee Break**
10:55 am
Predicting and mapping tumor regression following neoadjuvant immunotherapy
Janis M. Taube
11:10 am
The virtual molecular tumor board as a tool for the delivery of precision oncology
Carlo Bifulco
11:25 am
A new perspective on therapy-modulated tumor antigenicity
Sandra Demaria
11:40 am
Cancer vaccine concepts for solving infectious diseases
Luigi Buonaguro
11:55 am
PDL1 and IDO targeting vaccination for treatment of metastatic cancer
Inge Marie Svane
12:10 pm
Discussion
12:25 pm
SYMPOSIUM – Non-Melanoma Skin Cancer
Chairpersons: Paolo A. Ascierto
Paolo A. Ascierto, Dirk Schadendorf
01:15 pm
Lunch**
GREAT DEBATE SESSION
Chairpersons: Paolo A. Ascierto, Bernard Fox, Igor Puzanov
02:00 pm
Can vaccine transform cold into hot tumors? Yes or No
Olivera Finn, Lisa H. Butterfield
02:30 pm
Discussion
02:40 pm
Data science approaches to gain insights in to IO development:
broad vs deep analytics
Theresa LaValle, Andrew Futreal
03:10 pm
Discussion
03:20 pm
Coffee Break**
SESSION
NEO ADJUVANT IMMUNOTHERAPY ACROSS CANCERS
Chairpersons: Paolo A. Ascierto, Elizabeth Burton
03:30 pm
Overview and GU cancer
Padmanee Sharma
03:45 pm
Breast Cancer
Elizabeth Mittendorf
04:00 pm
Colon cancer
Myriam Chalabi
04:15 pm
NSCLC
Tina Cascone
04:30 pm
Melanoma
Rodabe Amaria
04:45 pm
NMSC as Model for Neoadjuvant Immunotherapy
Neil Gross
05:00 pm
Refining pathological response assessment in neoadjuvant therapy for melanoma
Richard Scolyer
05:15 pm
Discussion
05:45 pm
Conclusions
Paolo A. Ascierto, Bernard Fox, Igor Puzanov
